S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NYSE:NVO

Novo Nordisk A/S (NVO) Price Target & Analyst Ratings

$103.20
-1.27 (-1.22%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$102.12
$104.26
50-Day Range
$99.91
$116.93
52-Week Range
$91.51
$122.16
Volume
2.59 million shs
Average Volume
1.51 million shs
Market Capitalization
$233.54 billion
P/E Ratio
30.81
Dividend Yield
1.43%
Price Target
$682.43

Novo Nordisk A/S Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 19 Analyst Ratings

Consensus Analyst Price Target

$440.00
326.36% Upside
High Prediction$750.00
Average Prediction$440.00
Low Prediction$130.00
TypeCurrent
8/8/21 to 8/8/22
1 Month Ago
7/9/21 to 7/9/22
3 Months Ago
5/10/21 to 5/10/22
1 Year Ago
8/8/20 to 8/8/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$440.00$440.00$130.00N/A
Predicted Upside326.36% Upside295.33% Upside15.29% UpsideN/A
Get Novo Nordisk A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


NVO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novo Nordisk A/S Stock vs. The Competition

TypeNovo Nordisk A/SMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside326.36% Upside516.68% Upside18.66% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
375
59.34%
Underperform Votes
257
40.66%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/15/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight
6/28/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell
6/27/2022Exane BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Parkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral750.00
6/7/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight
5/31/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
5/12/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight850.00 ➝ 875.00
5/5/2022Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral
5/4/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target850.00 ➝ 900.00
4/25/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$130.00+16.15%
4/19/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold585.00 ➝ 780.00
3/2/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
2/28/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
2/3/2022Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
1/25/2022Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Sell
11/4/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
10/29/2021DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/18/2021SEB Equities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carsten Lonborg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
8/5/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
11/3/2020Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell
11/22/2019Pareto Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/30/2019Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Underperform
(Data available from 8/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Novo Nordisk A/S Price Target - Frequently Asked Questions

What is Novo Nordisk A/S's consensus rating and price target?

According to the issued ratings of 19 analysts in the last year, the consensus rating for Novo Nordisk A/S stock is Hold based on the current 2 sell ratings, 6 hold ratings and 11 buy ratings for NVO. The average twelve-month price prediction for Novo Nordisk A/S is $440.00 with a high price target of $750.00 and a low price target of $130.00. Learn more on NVO's analyst rating history.

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Analysts like Novo Nordisk A/S less than other Medical companies. The consensus rating for Novo Nordisk A/S is Hold while the average consensus rating for medical companies is Buy. Learn more on how NVO compares to other companies.

Do MarketBeat users like Novo Nordisk A/S more than its competitors?

MarketBeat users like Novo Nordisk A/S less than other Medical companies. 59.34% of MarketBeat users gave Novo Nordisk A/S an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is Novo Nordisk A/S being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Novo Nordisk A/S's stock had 5 upgrades and 1 downgrade by analysts.

Does Novo Nordisk A/S's stock price have much upside?

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 295.33% based on their 12-month price targets.

What analysts cover Novo Nordisk A/S?

Novo Nordisk A/S has been rated by Barclays, BNP Paribas, Exane BNP Paribas, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:NVO) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.